Targeting the mTOR pathway in neuroendocrine tumors.
Neuroendocrine tumors (NETs) are rare, generally indolent tumors that are lethal in the metastatic setting. Treatment options to control tumor growth are limited. In clinical trials, investigational oral mammalian target of rapamycin (mTOR) inhibitors have shown activity in patients with metastatic NETs. The purpose of this article is to provide oncology nurses with a background on the mechanism of action of mTOR inhibitors in the setting of NETs. Increased understanding of the role of mTOR in the pathogenesis of NETs has led to the study of mTOR inhibitor investigational agents in NETs. Treatments are evolving and currently focusing on targeted agents such as mTOR inhibitors. Understanding the mechanisms of action of targeted agents is a critical component of nursing knowledge.
Gardner
Nancy
N
Robert Wood Johnson University Hospital, and School of Nursing, Rutgers University, Newark, NJ, USA. nancymgardner@msn.com
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018278:Carcinoma, Neuroendocrine / Q000188:drug therapy* / Q000378:metabolism / Q000451:nursing; D006801:Humans; D011494:Protein Kinases / Q000187:drug effects*; D058570:TOR Serine-Threonine Kinases
D000970:Antineoplastic Agents; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases